Clinical trials: Suppurative Hidradenitis
Hidradenitis Suppurativa (HS)
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS).
- Trial name
- NCT07109765
- Testing
- Secukinumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College
Hidradenitis Suppurativa, Acne Inversa
Efficacy of Laser Hair Removal Therapy in HS
Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin disorder, characterized by painful inflamed nodules, abscesses and tunnels in the skin folds such as the axilla, inguinal region and gluteal…
- Trial name
- HaLa (NCT05762484)
- Testing
- Nd:YAG laser hair removal, Clindamycin 1 % Topical Lotion
- Volunteers
- 58 people
- Sponsor
- Erasmus Medical Center
Hidradenitis Suppurativa
Hidradenitis Suppurativa Patient Experience With Humira Treatment
Hidradenitis suppurativa (HS) is a chronic relapsing condition with significant psychosocial impact and morbidity, but that doesn't mean that patients will necessarily be adherent to recommended treatments.
- Trial name
- NCT04132388
- Testing
- Electronic Reporting, Adalimumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Hidradenitis Suppurativa
Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa
The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study.
- Trial name
- NCT01063270
- Testing
- Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Hidradenitis Suppurativa
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult…
- Trial name
- DETERMINED 1 (NCT03926169)
- Testing
- Risankizumab
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 243 people
- Sponsor
- AbbVie
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa Wound Care
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape.
- Trial name
- NCT04354012
- Testing
- methylene blue, gentian violet, and ovine forestomach wound dressings
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Inflammatory Bowel Diseases, Ulcerative Colitis
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid
- Trial name
- MISTIC (NCT04191395)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c.
- Conditions
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
- Trial name
- NCT07261072
- Testing
- Topical injection of Secukinmab, Subcutaneous injection of Secukinumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College
Hidradenitis Suppurativa
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the…
- Trial name
- NCT07665437
- Testing
- Remibrutinib
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 710 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
The goal of this clinical trial is to learn if combining an IL-17A/F monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS).
- Trial name
- NCT07554014
- Testing
- IL-17A/F mAb + NAFL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (Acne Inversa)
HS ABSCESSES: I&D VS PUNCH DEBRIDEMENT
This randomized-control trial is designed to determine the recurrence rate of HS abscesses following drainage via two methods: I\&D with a linear incision and PD with an 8mm punch biopsy.
- Trial name
- HSPUNCH (NCT06731309)
- Testing
- Punch Debridement, Incision and Drainage
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- Erasmus Medical Center
Hidradenitis Suppurativa, Hidradenitis
Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
To establish the safety of radiotherapy in the treatment of advanced hidradenitis suppurativa. Patients will receive radiotherapy treatment over one week and then they will be followed for the next three months.
- Trial name
- RTHS (NCT03040804)
- Testing
- Low dose Radiotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Hidradenitis Suppurativa
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.
- Trial name
- SPECTRA (NCT06444087)
- Testing
- secukinumab
- Where
- 22 sites in France
- Volunteers
- 192 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent…
- Trial name
- STOP-HS LTE (NCT06212999)
- Testing
- Povorcitinib
- Where
- 165 sites in United States, Australia and 15 more
- Volunteers
- 617 people
- Sponsor
- Incyte Corporation
Axillary Hidradenitis Suppurativa
Perforator Flaps for Axillary Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a recurrent inflammatory disease (< 2 episode /6 months) with 1%-4% prevalence in Europe. Suppurating lesions are painful and involve one or more regions (axilla, genitofemoral, perineum, gluteal…
- Trial name
- HS-PAX (NCT03784313)
- Testing
- skin repair by axillary perforator flaps, skin repair by secondary wound healing
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hidradenitis Suppurativa
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT03607487
- Testing
- INCB054707
- Where
- 13 sites in Canada, Denmark and 1 more
- Volunteers
- 35 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a…
- Trial name
- NCT06645821
- Testing
- EVO101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Virginia Clinical Research, Inc.